

NEPHROTEST - NephroTest

Head :Stengel Bénédicte, INSERM U1018 CENTRE DE RECHERCHE EN ÉPIDÉMIOLOGIE ET SANTÉ DES POPULATIONS
Froissart , UMR 872 EQ.3

Last update : 08/12/2014 | Version : 2 | ID : 60132

General

Identification

| | |
|--|-----------------------------|
| Detailed name | NephroTest |
| Sign or acronym | NEPHROTEST |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CPP 09298, CNIL DR 2010-149 |

General Aspects

| | |
|--------------|--|
| Medical area | Urology, andrology and nephrology |
| Keywords | renal function, glomerular filtration rate, vascular and metabolic complications, renal replacement therapy, Health episodes, quality of life, mortality |

Scientific investigator(s) (Contact)

| | |
|----------------------|--|
| Name of the director | Stengel |
| Surname | Bénédicte |
| Address | 94807 VILLEJUIF CEDEX |
| Phone | + 33 (0)1 45 59 50 39 |
| Email | benedicte.stengel@inserm.fr |
| Unit | INSERM U1018 CENTRE DE RECHERCHE EN ÉPIDÉMIOLOGIE ET SANTÉ DES POPULATIONS |
| Organization | INSERM |
| Name of the director | Froissart |
| Address | 75006 PARIS |

| | |
|--------------|----------------------------------|
| Phone | + 33 (0)1 56 09 39 73 |
| Email | marc.froissart@parisdescartes.fr |
| Unit | UMR 872 EQ.3 |
| Organization | INSERM |

Collaborations

Funding

| | |
|----------------|-------|
| Funding status | Mixed |
|----------------|-------|

| | |
|---------|---|
| Details | Ministère de la recherche, INSERM, Agence de Biomédecine, Laboratoires Roche, AMGEN |
|---------|---|

Governance of the database

| | |
|---|--------|
| Sponsor(s) or organisation(s) responsible | INSERM |
| Organisation status | Public |

Additional contact

Main features

Type of database

| | |
|--|---|
| Type of database | Study databases |
| Study databases (details) | Cohort study |
| Database recruitment is carried out by an intermediary | A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study | No |
| Additional information regarding sample selection. | Prospective Inclusion cut-off date not determined |

Database objective

| | |
|----------------|---|
| Main objective | General objective: To identify new biomarkers along with environmental and genetic risk factors for chronic kidney disease progression and related complications Secondary objectives: - To describe the natural history of chronic kidney disease in terms of optimised treatment according to |
|----------------|---|

international recommendations - To evaluate the realisation and relevance of the recommended objectives (K/DOQI, KDIGO, HAS)

Inclusion criteria

Patients over 18 years of age with chronic kidney disease confirmed by the presence of kidney damage markers: biological, morphological or histological abnormalities and glomerular filtration rate measurement by reference method (renal clearance of ⁵¹Cr-EDTA), stages 1-5 of the 2005 KDIGO classification, not on dialysis and not grafted.

Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)

Population covered

Sick population

Gender

Male
Woman

Geography area

Local

French regions covered by the database

Aquitaine Limousin Poitou-Charentes
Île-de-France

Detail of the geography area

Multicentric cohort (3 centres) throughout France (Ile de France and Bordeaux)

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)

01/2001

Date of last collection (YYYY or MM/YYYY)

12/2012

Size of the database

Size of the database (number of individuals)

[1000-10 000[individuals

Details of the number of individuals

1835

Data

| | |
|--|--|
| Database activity | Data collection completed |
| Type of data collected | Clinical data Declarative data Paraclinical data Biological data |
| Clinical data (detail) | Direct physical measures Medical registration |
| Declarative data (detail) | Paper self-questionnaire Face to face interview |
| Paraclinical data (detail) | Imaging (pulse wave velocity, bioimpedance) |
| Biological data (detail) | Type of samples taken: blood and urine |
| Presence of a biobank | Yes |
| Contents of biobank | Serum Plasma Fluids (saliva, urine, amniotic fluid, ?) DNA |
| Details of biobank content | Serum bank, plasma bank, DNA bank, urine bank in progress |
| Health parameters studied | Health event/morbidity Health event/mortality Quality of life/health perception |
| Procedures | |
| Data collection method | Self-administered questionnaire: input from a paper questionnaire (manual input) Interview: input from a paper questionnaire (manual input) Clinical examinations handwritten (manual input) Biological analysis: direct input (Other) Other collection for biological analysis: direct import from laboratory data management system (interfaces) |
| Participant monitoring | Yes |
| Details on monitoring of participants | (Indefinite duration) |
| Links to administrative sources | Yes |
| Linked administrative sources (detail) | Pathology register |
| Promotion and access | |

Promotion

Link to the document <http://www.hal.inserm.fr/NEPHROTEST>

Description List of publications in HAL

Link to the document <http://tinyurl.com/Pubmed-NEPHROTEST>

Description List of publications in Pubmed

Access

Terms of data access (charter for data provision, format of data, availability delay) Data may be used by academic teams Data may be used by industrial teams via the industrial steering committee

Access to aggregated data Access on specific project only

Access to individual data Access on specific project only